Post a Free Blog

Submit A Press Release

At CWEB, we are always looking to expand our network of strategic investors and partners. If you're interested in exploring investment opportunities or discussing potential partnerships and serious inquiries. Contact: jacque@cweb.com

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessRoche Holding AG's Strong Financial Performance in 2024

Roche Holding AG’s Strong Financial Performance in 2024

Add to Favorite
Added to Favorite


Earnings Per Share (EPS) of $1.20, surpassing the estimated $1.17, reflecting the company’s ability to exceed market expectations.
Revenue reached approximately $34.1 billion, exceeding forecasts and highlighting Roche’s strong market position.
2024 sales of $68.7 billion, driven by a 7% year-over-year sales growth at constant exchange rates.

Roche Holding AG, listed as PNK:RHHBY, is a leading player in the pharmaceutical and diagnostics industry. The company is known for its innovative healthcare solutions, focusing on both pharmaceuticals and diagnostics. Roche competes with other major pharmaceutical companies like Novartis and Pfizer. The company has a strong portfolio of drugs, including treatments for cancer, multiple sclerosis, and hemophilia.

On January 30, 2025, Roche reported earnings per share (EPS) of $1.20, surpassing the estimated $1.17. This positive performance reflects the company’s ability to exceed market expectations. Roche’s revenue also exceeded forecasts, reaching approximately $34.1 billion compared to the estimated $33.8 billion. This achievement highlights the company’s strong market position and effective business strategies.

Roche’s Q4 2024 earnings call, held on January 30, 2025, featured key executives like CEO Thomas Schinecker and CFO Alan Hippe. The call was attended by analysts from major financial institutions, ensuring a comprehensive analysis of the company’s performance. As highlighted by Seeking Alpha, the call was conducted in a listen-only mode, allowing for a smooth presentation of financial results and strategic plans.

In 2024, Roche achieved sales of $68.7 billion, surpassing the Zacks Consensus Estimate of $68 billion. The company’s earnings per American Depositary Receipt were $2.67, beating the expected $2.56. This success was driven by a 7% year-over-year sales growth at constant exchange rates, fueled by strong demand for key drugs like Vabysmo and Phesgo. The Pharmaceuticals Division saw an 8% increase in sales, reaching CHF 46.2 billion.

Roche aims for a high single-digit percentage increase in core EPS for 2025, adjusted for currency fluctuations. This growth is expected to be driven by reduced costs and the success of drugs like Vabysmo and Phesgo. The company’s total operating profit, adjusted for one-time items, reached 20.8 billion Swiss francs in 2024, slightly below market expectations. Roche’s financial metrics, such as a P/E ratio of 2.71 and a debt-to-equity ratio of 1.25, indicate a strong financial position.

Subscribe to get Latest News Updates

Latest News

You may like more
more